Home | Publications | Diagnostics place holder
place holder place holder

Diagnostics

Evaluation of Product Usage for Molecular Testing for Infectious Diseases


Publication Date   August 2004
Publisher   HSB Consulting
Product Type   Report
Pages   not applicable
ISBN Number   not applicable
Product Code   HBS017
Ask a question about this product?

Price £6,780.00

approximately: $12,668 | €8,599

Summary


Key Project Objectives:
* Assessment of the current usage of molecular techniques for Infectious Disease testing within routine diagnostics.
* Future Outlook

Deliverables:
* Description of laboratory landscape per country
* Market Quantification
Number of performed tests for 42 pathogens
Number of laboratories that test the pathogen
Split of used technologies and manufacturers per pathogen
Market size per pathogen
Market shares per pathogen and total
Growth expectations
* Market Qualification
Regulatory issues per country (legislation, reimbursement)
Understand decision making criteria and influencers
- who is responsible for the decision
- how is equipment financed
- what finance models do lab prefer (tender, contract etc.)
Price acceptance of new tests
Drivers and restraints per country
Influences of the IVD Act

Segmentation by type of laboratory:
* Private laboratories
* Public laboratories (university & hospital based)

Segmentation by technology:
* commercial available tests with amplification (methods: PCR, LCR, SDA)
* Commercial tests without amplification (method: DNA probes)
* Others: EIA (enzyme linked tests), Antibody/Antigen-complex tests, serology, microscopy, strip tests

Segmentation by country:
* Germany
* Sweden
* France
* Denmark
* Italy
* Switzerland
* UK
* Norway
* Spain
* Finland
* Belgium

Content


1.1 Project Objectives

1.2 Definitions
1.3 German Health Care System and Reimbursement
1.4 German Laboratory Landscape
1.5 Respondent Population Germany

2.1 Sexual Transmitted Diseases (STD)

Chlamydia Trachomatis
Neisseria
HIV
HCV
Group B Streptococcus
HSV
2.2 Mycobacteria
Mycobacteria Tuberculosis
Mycobacteria Avium
Mycobacteria – NA Purification
2.3 Atypical Pneumoniae
Bordetella
Legionella
Chlamydia sp.
Mycoplasma Pneumoniae
2.4 Cytomegalovirus (CMV)
CMV – Qualitative Tests
CMV – Quantitative Tests
2.5. Viral Meningitis
HSV 1 & 2
Enterovirus
West Nile Virus (WNV)
Epstein Barr Virus (EBV)
VZV
2.6 Respiratory Viruses
SARS
Adenovirus
Influenza A
Influenza A&B
RSV
Parainfluenza
2.7 HPV
2.8 Chronic Meningitis
2.9 Bacterial Meningitis
Neisseria Meningitis
Haemophilus Influenza
Pneumococcae
Listeria
Enterobacteria
2.10 Tick Born Encephalitis
2.11 Antibiotic Resistant Bacteria
2.12 Candida

3. Equipment amp; Purchase

3.1 Current Installations & Financing of Laboratory Equipment
Cobas Amplicor, Roche
Light Cycler, Roche
ABI PRISM, Applied Biosystems
RotorGene, Corbett Research
Other Cycler
Other Devices/Manufacturers
3.2 Budget Resources
3.3 Who is Involved in Purchasing Decisions
3.4 How do Laboratories Purchase
3.5 Criteria Influence a Purchasing Decision
3.6 What are Laboratories Willing to Pay for New Tests?

4. Market Sizes and Market Shares

4.1 Market Volumes for Selected Pathogens
STD
Mycobacteria Tuberculosis
Atypical Pneumonia
CMV
Viral Meningitis
Respiratory Viruses
HPV
MRSA
4.2 Market Shares

5. Market Trends

5.1 Problems with Molecular Diagnostics
5.2 Expected Growth per Segment
6.3 Other Growth Areas
5.4 Drivers for Molecular Diagnostics
5.5 Restraints for Molecular Diagnostics

6. Political Influences

6.1 Changes of Reimbursement Policy
6.2 Influence of the EU IVD Act